NewsRx

Search our medical news database

Helicobacter pylori (Diagnostics)

License Granted for H. Pylori In Vitro Diagnostic Tests

Published in Cancer Weekly, November 25th, 1996

OraVax, Inc., Cambridge, Massachusetts, announced it has entered into a licensing agreement with bioMerieux Vitek, Inc., granting rights to develop human diagnostic products incorporating a proprietary OraVax antigen.

The antigen, called CagA, is a component of Helicobacter pylori and is expected to be used in the development of diagnostic products for the detection of H. pylori infection. CagA is one of several antigens OraVax is evaluating for inclusion in its vaccines against H. pylori.

An estimated 30 percent of U.S. citizens are infected with H. pylori bacteria, with infection rates in other parts of the world...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook